Tag: expenses

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Lucas GC Limited (NASDAQ: LGCL) (“Lucas” or the “Company”), an artificial intelligence (“AI”) technology-driven Platform-as-a-Service (“PaaS”) company with proprietary technologies applied to the human resources and insurance industry verticals, today announced the closing of its “best efforts” follow-on offering (the "Offering") of 32,150,000 ordinary shares, par value US$0.000005 per share, of the Company (the "Ordinary Shares") at a public offering price of US$0.20 per share, for total gross proceeds of US$6,430,000 before deducting placement agent's fee and offering expenses.

Hong Kong, June 23, 2025 (GLOBE NEWSWIRE) -- Happy City Holdings Limited (Nasdaq: HCHL) (the “Company”), an established all-you-can-eat hotpot restaurant operator in Hong Kong , today announced the pricing of its initial public offering (the “Offering”) of 1,100,000 Class A ordinary shares (the “Class A Ordinary Shares”), at a price of $5.00 per Class A Ordinary Share (the “Offering Price”).

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (“Ninepoint Partners”) today announced the June 2025 cash distributions for its ETF Series securities. The record date for the distributions is June 30, 2025. All distributions are payable on July 8, 2025.

(VXC, VUS, VUN, VSP, VFV, VGH and VGG)

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- AGF Investments Inc. (AGF Investments) today announced the June 2025 cash distributions for AGF Enhanced U.S. Equity Income Fund*, AGF Total Return Bond Fund* and AGF Systematic Global Infrastructure ETF, which pay monthly distributions, as well as AGF Global Sustainable Growth Equity ETF, which pays quarterly distributions. Unitholders of record on June 30, 2025 will receive cash distributions payable on July 7, 2025.

Fueled by 5G and digital transformation, the market is set to reach $25B by 2030. Key regions like North America and Asia-Pacific drive growth, with evolving technology trends enhancing efficiency and capacity. Challenges include R&D expenses and supply chain issues.

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.